Cargando…

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

The objective of this exploratory, open-label, single-arm, phase II clinical trial was to evaluate plitidepsin (5 mg/m(2)) administered as a 3-hour continuous intravenous infusion every two weeks to patients with locally advanced/metastatic transitional cell carcinoma of the urothelium who relapsed/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumez, Herlinde, Gallardo, Enrique, Culine, Stephane, Galceran, Joan Carles, Schöffski, Patrick, Droz, Jean P., Extremera, Sonia, Szyldergemajn, Sergio, Fléchon, Aude
Formato:	Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International 2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763111/ https://www.ncbi.nlm.nih.gov/pubmed/19841725 http://dx.doi.org/10.3390/md7030451

Ejemplares similares

Plitidepsin Has a Safe Cardiac Profile: A Comprehensive Analysis
por: Soto-Matos, Arturo, et al.
Publicado: (2011)

Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma
por: Schöffski, Patrick, et al.
Publicado: (2009)

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
por: Plummer, R, et al.
Publicado: (2013)

Plitidepsin for multiple myeloma
Publicado: (2019)

Plitidepsin: design, development, and potential place in therapy
por: Alonso-Álvarez, Sara, et al.
Publicado: (2017)

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
por: Martinez, Miguel Angel
Publicado: (2021)

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
por: Spicka, Ivan, et al.
Publicado: (2019)

c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity
por: Muñoz-Alonso, María J., et al.
Publicado: (2013)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

The use of multispectral imaging to distinguish reactive urothelium from neoplastic urothelium
por: Gilbert, Christopher Michael, et al.
Publicado: (2010)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

Signalling Molecules in the Urothelium
por: Winder, Michael, et al.
Publicado: (2014)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
por: Varona, Jose F, et al.
Publicado: (2022)

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients
por: Roubaud, Guilhem, et al.
Publicado: (2015)

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Mateos, María Victoria, et al.
Publicado: (2022)

Tumorigenicity of RTK/RAS in urothelium
por: Wu, Xue-Ru, et al.
Publicado: (2015)

Small cell cancer of the bladder: The Leon-Berard cancer centre experience
por: Ismaili, Nabil, et al.
Publicado: (2008)

Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience
por: Heudel, Pierre, et al.
Publicado: (2009)

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
por: Rodon, Jordi, et al.
Publicado: (2021)

Does the Urothelium of Old Mice Regenerate after Chitosan Injury as Quickly as the Urothelium of Young Mice?
por: Erzar, Eva, et al.
Publicado: (2020)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
por: Cheng, Ke, et al.
Publicado: (2022)

Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19
por: Papapanou, Michail, et al.
Publicado: (2021)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Mechanotransduction in the urothelium: ATP signalling and mechanoreceptors
por: Li, Xu, et al.
Publicado: (2023)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis
por: Sachse, Martin, et al.
Publicado: (2022)

Outcome of recurrent and metastatic small cell carcinoma of the bladder
por: Ismaili, Nabil, et al.
Publicado: (2009)

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
por: Schinzari, Giovanni, et al.
Publicado: (2018)

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
por: White, Kris M., et al.
Publicado: (2021)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Posterior scleritis after biweekly aflibercept intravitreal injections
por: Hébert, Mélanie, et al.
Publicado: (2022)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

The urothelium of a hibernator: the American black bear
por: Spector, David A, et al.
Publicado: (2015)

Age-related endolysosome dysfunction in the rat urothelium
por: Truschel, Steven T., et al.
Publicado: (2018)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
por: Guisado-Vasco, P., et al.
Publicado: (2021)

How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study
por: Da Silva, Angélique, et al.
Publicado: (2022)

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
por: Culine, Stéphane, et al.
Publicado: (2023)

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
por: Baek, Jin Ho, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_qnv406og1p6ha7eqjiq0pccoi5